Chaoting Zhang#, Qin Tan#, Shance Li#, Luyan Shen, Jingtao Zhang, Ying Liu, Wenjun Yang*, Zheming Lu*. Induction of EBV latent membrane protein-2A (LMP2A) specific T cells and construction of individualized TCR-engineered T cells for EBV associated malignancies.,Journal for Immunotherapy of Cancer,9(7):e002516.

Chaoting Zhang#, Yizhe Sun#, Shance Li, Luyan Shen, Xia Teng, Yefei Xiao, Nan Wu*, Zheming Lu* Autophagic flux restoration enhances the antitumour efficacy of tumour infiltrating lymphocytes,Journal for ImmunoTherapy of Cancer,10(10):e004868

Hui Liu#, Wen Lei#, Chaoting Zhang#, Chunmei Yang, Juying Wei, Qunyi Guo, Xiaojun Guo, Zhilu Chen, Ying Lu, Ken H Young*, Zheming Lu*, Wenbin Qian*. CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma,Clinical cancer research,27(2):473-484

Chaoting Zhang#, Heyilimu Palashati#, Zhuona Rong, Ningjing Lin, Luyan Shen, Ying Liu, Shance Li, Bentong Yu*, Wenjun Yang*, Zheming Lu*. Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies,Molecular cancer,19(1):162

Tan Qin, Zhang Chaoting*, Yang Wenjun, Liu Ying, Heyilimu Palashati, Feng Dongdong, Xing Liying, Ke Yang*, Lu Zheming*. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma,Journal for Immunotherapy of Cancer,7(1):232

Chaoting Zhang#, Yizhe Sun#, Shance Li, Luyan Shen, Xia Teng, Yefei Xiao, Ping Zhou*, Zheming Lu* Autophagic flux restoration of senescent T cells improves antitumor activity of TCR-engineered T cells.,Clin Transl Immunology,11(9):e1419

Zhang Chaoting#, Ding Huirong#, Huang Hongying, Heyilimu Palashati, Miao Yu, Xiong Hongchao*, Lu Zheming*. TCR repertoire intratumor heterogeneity of CD4+ and CD8+ T cells in centers and margins of localized lung adenocarcinomas,International journal of cancer,144(4):818-827

Zhang Chaoting#, Heyilimu Palashati#, Tan Qin, Ku Wenjing, Miao Yu, Xiong Hongchao*, Lu Zheming* Immediate and substantial evolution of T cell repertoire in peripheral blood and tumor microenvironment of patients with esophageal squamous cell carcinoma treated with preoperative chemotherapy,Carcinogenesis,39(11):1389-1398

北京市科技新星, 北京市科技新星, 第1完成人, 北京市科学技术委员会, 2023.11

第六届全国临床创新与发明大赛, 一等奖, 第1完成人, 中国医学装备协会, 2021.4

2020年首度青年医学创新与转化大赛, 二等奖, 第1完成人, 北京医学会, 2020.11

含有膜型IL7的融合蛋白及T细胞, 发明专利, 第2完成人, 国家知识产权局, 中国, 2023.10

一种筛选肿瘤特异TCR的方法, 发明专利, 第1完成人, 国家知识产权局, 中国, 2022.4

一种同时表达靶向CD19和CD20的CAR与PD1-CD28嵌合受体的慢病毒载体, 发明专利, 第2完成人, 国家知识产权局, 中国, 2020.7

靶向TRBC1 CAR-T细胞的制备方法与应用, 发明专利, 第2完成人, 国家知识产权局, 中国, 2020.7

肿瘤浸润T 细胞的功能修复及其肿瘤特异TCR 的高效筛选, 课题负责人, 2023.11.1～2026.10.30, 北京市科技新星

免疫耗竭T细胞的功能恢复及其TCR的体内外功能验证, 课题负责人, 2021.1.1～2023.12.31, 国家自然科学基金

免疫功能耗竭T细胞的TCR用于抗肿瘤TCR-T研究, 课题负责人, 2018.1.1～2020.12.31, 北京市自然科学基金面上项目

外周血T细胞相关标志物动态监测预测非小细胞肺癌患者PD-1抗体治疗导致的疾病超进展, 课题负责人, 2020.5.1～2023.4.30, 北京市首都卫生发展科研专项项目

肿瘤特异TCR的体内筛选及TCR-T体内外功能验证, 课题负责人, 2020.1.1～2022.12.31, 北京市医院管理局青年人才培养“青苗”计划

肿瘤微环境中脂质ROS/胆固醇代谢的免疫抑制效应与干预策略, 课题负责人, 2022.1.1～2022.12.31, 临床医学+X青年专项